{"id":"https://openalex.org/W2159298060","doi":"https://doi.org/10.1086/599115","title":"Efavirenz and Nevirapine Interactions with Rifampicin: Resolving the Dilemmas?","display_name":"Efavirenz and Nevirapine Interactions with Rifampicin: Resolving the Dilemmas?","publication_year":2009,"publication_date":"2009-05-13","ids":{"openalex":"https://openalex.org/W2159298060","doi":"https://doi.org/10.1086/599115","mag":"2159298060","pmid":"https://pubmed.ncbi.nlm.nih.gov/19438396"},"language":"en","primary_location":{"id":"doi:10.1086/599115","doi":"https://doi.org/10.1086/599115","is_oa":false,"landing_page_url":"https://doi.org/10.1086/599115","pdf_url":null,"source":{"id":"https://openalex.org/S72350973","display_name":"Clinical Infectious Diseases","issn_l":"1058-4838","issn":["1058-4838","1537-6591"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Infectious Diseases","raw_type":"journal-article"},"volume":null,"type":"editorial","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5056603667","display_name":"Umesh Lalloo","orcid":"https://orcid.org/0000-0002-5950-3118","observed_orcids":["https://orcid.org/0000-0002-5950-3118"]},"institutions":[{"id":"https://openalex.org/I95023434","display_name":"University of KwaZulu-Natal","ror":"https://ror.org/04qzfn040","country_code":"ZA","type":"education","lineage":["https://openalex.org/I95023434"]}],"countries":["ZA"],"is_corresponding":true,"raw_author_name":"Umesh\u00a0G. Lalloo","raw_affiliation_strings":["Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Congella, South Africa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Congella, South Africa","institution_ids":["https://openalex.org/I95023434"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5056603667"],"corresponding_institution_ids":["https://openalex.org/I95023434"],"apc_list":{"value":4763,"currency":"USD","value_usd":4763},"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":16,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"48","issue":"12","first_page":"1760","last_page":"1762"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9463000297546387,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9463000297546387,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10038","display_name":"Tuberculosis Research and Epidemiology","score":0.03009999915957451,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11381","display_name":"Infectious Diseases and Tuberculosis","score":0.006099999882280827,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/efavirenz","display_name":"efavirenz","score":0.9380000233650208},{"id":"https://openalex.org/keywords/nevirapine","display_name":"nevirapine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/rifampicin","display_name":"rifampicin","score":0.972000002861023},{"id":"https://openalex.org/keywords/drug-interactions","display_name":"drug interactions","score":0.921999990940094},{"id":"https://openalex.org/keywords/hiv-tb-co-infection","display_name":"HIV/TB coinfection","score":0.7630000114440918},{"id":"https://openalex.org/keywords/highly-active-antiretroviral-therapy","display_name":"highly active antiretroviral therapy","score":0.9010000228881836},{"id":"https://openalex.org/keywords/antiretroviral-therapy-timing","display_name":"antiretroviral therapy timing","score":0.6069999933242798},{"id":"https://openalex.org/keywords/tuberculosis-treatment","display_name":"tuberculosis treatment","score":0.675000011920929},{"id":"https://openalex.org/keywords/south-africa","display_name":"South Africa","score":0.6179999709129333}],"concepts":[{"id":"https://openalex.org/C2779130552","wikidata":"https://www.wikidata.org/wiki/Q263713","display_name":"Nevirapine","level":5,"score":0.893622875213623},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8640139102935791},{"id":"https://openalex.org/C2781432083","wikidata":"https://www.wikidata.org/wiki/Q422645","display_name":"Efavirenz","level":5,"score":0.7612760066986084},{"id":"https://openalex.org/C2778607973","wikidata":"https://www.wikidata.org/wiki/Q422652","display_name":"Rifampicin","level":3,"score":0.7450604438781738},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.4281843602657318},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3648107051849365},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.32331711053848267},{"id":"https://openalex.org/C2781069245","wikidata":"https://www.wikidata.org/wiki/Q12204","display_name":"Tuberculosis","level":2,"score":0.24214717745780945},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.15298676490783691},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.12017503380775452},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.11632844805717468}],"mesh":[{"descriptor_ui":"D000480","descriptor_name":"Alkynes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000900","descriptor_name":"Anti-Bacterial Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003521","descriptor_name":"Cyclopropanes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012293","descriptor_name":"Rifampin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D014376","descriptor_name":"Tuberculosis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019829","descriptor_name":"Nevirapine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D048588","descriptor_name":"Benzoxazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1086/599115","doi":"https://doi.org/10.1086/599115","is_oa":false,"landing_page_url":"https://doi.org/10.1086/599115","pdf_url":null,"source":{"id":"https://openalex.org/S72350973","display_name":"Clinical Infectious Diseases","issn_l":"1058-4838","issn":["1058-4838","1537-6591"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Infectious Diseases","raw_type":"journal-article"},{"id":"pmid:19438396","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19438396","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","raw_type":"Editorial"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":14,"referenced_works":["https://openalex.org/W1978353805","https://openalex.org/W1978540833","https://openalex.org/W2017771531","https://openalex.org/W2027554580","https://openalex.org/W2034227821","https://openalex.org/W2069614945","https://openalex.org/W2095597897","https://openalex.org/W2097781012","https://openalex.org/W2121600368","https://openalex.org/W2135989318","https://openalex.org/W2146921865","https://openalex.org/W2170150194","https://openalex.org/W2418210342","https://openalex.org/W2470303801"],"related_works":["https://openalex.org/W1978088338","https://openalex.org/W7098131299","https://openalex.org/W2050414099","https://openalex.org/W2415645848","https://openalex.org/W2527146017","https://openalex.org/W1676117","https://openalex.org/W2411880940","https://openalex.org/W2471467364","https://openalex.org/W1993727934","https://openalex.org/W7101008528"],"abstract_inverted_index":{"Tuberculosis":[0],"(TB)":[1],"is":[2,70,123,137,146,159,236,254],"the":[3,17,33,43,47,132,142,165,202,206,213],"most":[4],"common":[5],"opportunistic":[6],"infection":[7,136,228,248],"in":[8,37,66,76,95,125,154,229,240],"persons":[9,94,153],"with":[10,242,266],"human":[11],"immunodeficiency":[12],"virus":[13],"(HIV)":[14],"infection,":[15],"and":[16,39,58,112,186,212,249,268],"2":[18],"diseases":[19],"together":[20],"represent":[21],"a":[22,237,243],"deadly":[23],"duo":[24],"[1].":[25],"The":[26,119,189],"TB":[27,64,91,122,145,183,250],"epidemic":[28],"has":[29],"been":[30],"aggravated":[31],"by":[32,201],"HIV":[34,135,227,247],"epidemic,":[35],"particularly":[36],"developing":[38],"resource-limited":[40],"regions":[41],"of":[42,63,90,101,121,134,144,169,191,196,205,219,226,246],"world.":[44],"According":[45],"to":[46,80,148,175,260],"World":[48],"Health":[49],"Organization":[50],"(WHO),":[51],"there":[52,83],"were":[53,78,84],"9.2":[54],"million":[55,60,74],"new":[56,88],"cases":[57,62,89,150],"14.2":[59],"prevalent":[61],"globally":[65],"2006":[67,77],"[2].":[68,118,157],"It":[69,158],"estimated":[71,86],"that":[72,161,167,256],"1.2":[73],"deaths":[75],"attributable":[79],"TB.":[81],"Globally,":[82],"an":[85],"709,000":[87],"among":[92],"HIV-infected":[93],"2006.":[96],"Africa":[97,156],"accounts":[98,105,109],"for":[99,106,110,116,181],"85%":[100],"these":[102],"cases,":[103],"India":[104],"3.3%,":[107],"Europe":[108],"1.8%,":[111],"other":[113],"countries":[114,126,241],"account":[115],"9.4%":[117],"burden":[120,245],"increasing":[124],"such":[127],"as":[128],"South":[129,155],"Africa,":[130],"where":[131],"rate":[133],"still":[138],"very":[139],"high.":[140],"Currently,":[141],"incidence":[143],"close":[147],"1000":[149],"per":[151],"100,000":[152],"comforting":[160],"emerging":[162],"data":[163],"support":[164],"hypothesis":[166],"coadministration":[168],"highly":[170],"active":[171,182],"antiretroviral":[172],"treatment":[173,180,225,235,265],"(HAART)":[174],"patients":[176,230,262],"who":[177,231],"are":[178,232],"receiving":[179,233,263],"improves":[184],"morbidity":[185],"mortality":[187],"[3].":[188],"question":[190],"early":[192],"versus":[193],"delayed":[194],"introduction":[195],"HAART":[197,257],"should":[198],"be":[199,258],"answered":[200],"A5221":[203],"Study":[204,222],"Adult":[207],"AIDS":[208],"Clinical":[209],"Trials":[210],"Group":[211],"Cambodian":[214],"Early":[215],"vs.":[216],"Late":[217],"Introduction":[218],"Antiretrovirals":[220],"(CAMELIA)":[221],"[4].":[223],"Concurrent":[224],"anti-TB":[234,264],"top":[238],"priority":[239],"high":[244],"burden.":[251],"Therefore,":[252],"it":[253],"important":[255],"prescribed":[259],"eligible":[261],"confidence":[267],"safety.":[269]},"counts_by_year":[{"year":2020,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}